Scientists Discover a New Family of Antimicrobial Peptides From Ruminants That Kill Bacteria by Jamming Their Protein-Making Machinery

The researchers used genome mining to identify rumicidin genes across ruminant genomes. Peptides were produced and tested biochemically for translation inhibition using in vitro translation assays. The structural mechanism was determined by cryo-electron microscopy of the E. coli 70S ribosome-rumicidin complex. Antibacterial spectrum was assessed through standard susceptibility testing against multiple bacterial species. In vivo efficacy was tested in an animal infection model. Cytotoxicity to human cells was evaluated in vitro. Resistance mechanisms were characterized using bacterial knockout mutants.

The antimicrobial resistance crisis demands new antibiotics with novel mechanisms of action. Rumicidins represent a new antibiotic class that works by a well-defined structural mechanism — plugging the ribosome exit tunnel — which is distinct from most existing antibiotics. The combination of broad-spectrum activity, in vivo efficacy, lack of human cell toxicity, and atomic-resolution structural data makes them unusually complete candidates for antibiotic development. Published in Nature Communications, this represents a high-impact discovery in the antimicrobial peptide field.

Proline-rich antimicrobial peptides (PrAMPs) that target bacterial ribosomes have attracted increasing attention as potential antibiotics because they exploit a target (the ribosome) that is essential and highly conserved across bacteria but structurally distinct from human ribosomes. This study extends the known diversity of ribosome-targeting PrAMPs beyond previously characterized families (like apidaecins from insects) to ruminant mammals, demonstrating that evolution has independently arrived at this antimicrobial strategy across very different animal lineages. The structural precision of the cryo-EM data enables rational drug design based on the rumicidin scaffold.

While in vivo efficacy was demonstrated in an animal infection model, the specific model, dosing, and bacterial challenge details were not provided in the abstract. The SbmA transporter-dependent uptake pathway is a known vulnerability of PrAMPs — bacteria can develop resistance by losing this transporter. The identified efflux pump modification represents another resistance concern. Human pharmacokinetics, stability, and potential immunogenicity of these peptides in therapeutic use remain unknown. Translation from animal-derived peptides to human therapeutics requires extensive optimization.